IRD
HEALTHCAREOcuphire Pharma Inc
Live · NASDAQ · May 9, Close
What's Moving IRD Today?
No stock-specific AI insight has been generated for IRD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.26
Fundamentals
Trading
IRD News
20 articles- Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal DiseasesYahoo Finance·May 7, 2026
- Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy StudyYahoo Finance·May 7, 2026
- Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ StocksYahoo Finance·May 5, 2026
- Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) ProgramYahoo Finance·May 4, 2026
- Citizens Initiates Coverage of Opus Genetics (IRD)Yahoo Finance·May 1, 2026
- Opus Genetics to Participate in Leading Medical Conferences in May 2026Yahoo Finance·Apr 27, 2026
- Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingGlobeNewswire Inc.·Apr 10, 2026
- Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland CapitalGlobeNewswire Inc.·Apr 6, 2026
- Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026Yahoo Finance·Mar 24, 2026
- BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy RatingYahoo Finance·Mar 12, 2026
- Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 10, 2026
- Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate UpdateYahoo Finance·Mar 10, 2026
- Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- Opus Genetics to Present at Upcoming Investor Conferences in March 2026Yahoo Finance·Mar 3, 2026
- Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual MeetingYahoo Finance·Feb 27, 2026
- Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaYahoo Finance·Feb 25, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Feb 13, 2026
- Update: Opus Genetics Shares Rise After Announcement of $25 Million Private PlacementYahoo Finance·Feb 13, 2026
- Opus Genetics Announces $25 Million Private PlacementYahoo Finance·Feb 13, 2026
- Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026Yahoo Finance·Feb 2, 2026
All 20 articles loaded
Price Data
52-Week Range
$5.26
Fundamentals
Trading
About Ocuphire Pharma Inc
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases that threaten vision. Utilizing advanced research and proprietary gene-editing technologies, Opus aims to address critical unmet medical needs with transformative solutions designed to restore sight. The company's commitment to ocular health, coupled with its robust pipeline supported by ongoing clinical trials and strategic collaborations, positions Opus as a key player in the biotech sector. This innovative approach not only enhances patient outcomes but also presents significant value creation opportunities for investors interested in healthcare advancements.